cemka > Publications > Pharmaco-Economics

Sort publications on year

  • Pharmaco-Economics

    Estimated annual costs of prophylaxis and treatment of venous thromboembolic events associated with major orthopedic surgery in France

    TILLEUL P, LAFUMA A, COLIN X, OZIER Y

    Clin Appl Thromb Hemost ; 12(4):473-484

  • Pharmaco-Economics

    Cervical cancer screening and associated treatment costs in France

    BERGERON C, BREUGELMANS JG, BOUEE S, LORANS C, BENARD S, REMY V

    Gynécol Obstét Fertil ; 34:1036-1042

  • Pharmaco-Economics

    The economic burden of glaucoma and ocular hypertension

    ROULAND JF, BERDEAUX G, LAFUMA A

    Drugs Aging ; 22(4):315-321

  • Pharmaco-Economics

    DĂ©pistage de la rhĂ©tinopathie diabĂ©tique par des photographies du fond de l’oeil

    AUBERT JP, MASSIN P, AUDRAN G, BEN MEHIDI A, BERNIT B, BOUÉE S, BOUHASSIRA M, BOUROVITCH JC, ERGINAY A, ESCHWÈGE E, JAMET M, MARRE M, NOUGAIREDE M, TCHERNY-LESSENOT S

    RevPrat - Médecine Générale ; 19(692-693):588-592

  • Pharmaco-Economics

    Cost-effectiveness analysis of PMMA, silicone, or acrylic intra-ocular lenses in cataract surgery in four European countries

    SMITH A, LAFUMA A, BERDEAUX G , BERTO P, BRUEGGENJUERGEN B, MAGAZ S, AUFFARTH G, BREZIN A, CAPOROSSI A, MENDICUTE J

    Ophthalmic Epidemiol ; 12(5):343-351

  • Pharmaco-Economics

    Frequency and hospitalisation-related costs of manic episodes in patients with bipolar I disorder in France

    DE ZELICOURT M, DARDENNES R, VERDOUX H, GANDHI G, CHOMETTE E, KHOSHNOOD B, PAPATHEODOROU ML, EDGELL ET, EVEN C, FAGNANI F

    Pharmacoeconomics ; 2003;21(15):1081-1090

  • Pharmaco-Economics

    Effectiveness and cost of contraception in France (FACET study): a cohort study from the French National Healthcare Insurance Database.

    AGOSTINI A, GODARD C, LAURENDEAU C, BENMAHMOUD A, LAFUMA A, DOZ M, LEVY-BACHELOT L, GOURMELEN J, LINET T.

    European Journal of Obstetrics & Gynecology and Reproductive Biology ; 2018;229: 137–143

  • Pharmaco-Economics

    Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis.

    CHARBONNEL B, SIMON D, DALLONGEVILLE J, BUREAU I, DEJAGER S, LEVY-BACHELOT L, GOURMELEN J, DETOURNAY B.

    Pharmacoecon Open ; 2018;2(2):209-219

  • Pharmaco-Economics

    Le traitement du diabùte de type 2 en France est dynamique plutît qu’inerte : analyse des prescriptions de 847 122 patients.

    ROUSSEL R, FONTAINE P, GOUET D, SERUSCLAT P, MARTINEZ L, DETOURNAY B, MARTIN-KRISTENSEN M.

    Med Mal Metab ; 2018;12(4):346-352

  • Pharmaco-Economics

    Clinical outcomes of glaucoma Treatments Over a patient lifetime : a Markov Model

    NORDMANN JP, LAFUMA A, DESCHASEAUX-VOINET C, BERDEAUX G

    J Glaucoma ; 14(6):463-469

  • Pharmaco-Economics

    Medical predictive Factors of Glaucoma Treatment Costs

    DENIS P, LAFUMA A, BERDEAUX G

    J Glaucoma ; 13(4):283-290

  • Pharmaco-Economics

    Le point de vue de l’Ă©conomiste de la santĂ© in “Evaluation des mĂ©dicaments aprĂšs la commercialisation – IntĂ©rĂȘts, objectifs et consĂ©quence

    FAGNANI F

    John Libbey Eurotext ; 59-62

  • Pharmaco-Economics

    Hepatitis B management costs in France, Italy, Spain, and the United Kingdom

    BROWN RE, DE COCK E, COLIN X, ANTONANZAS F, ILOEJE UH

    J Clin Gastroenterol ; 38(10 Suppl):S169-174

  • Pharmaco-Economics

    Economic evaluation of a combined DTPa, Hepatitis B, Polio, Hib vaccine Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule

    FAGNANI F, LE FUR C, DURAND I, GIBERGY M

    Eur J Health Econom ; 5(2):143-149

  • Pharmaco-Economics

    Donepezil for the treatment of mild to moderate Alzheimer’s disease in France: the economic implications

    FAGNANI F, LAFUMA A, PECHEVIS M, RIGAUD AS, TRAYKOV L, SEUX ML, FORETTE F

    Dement Geriatr Cogn Disord ; 17(1-2):5-13